Objective To explore the change characteristics of the cerebrospinal fluids matrix metalloproteinase-9 (MMP-9) in different severity levels of hypoxic-ischemic encephalopathy (HIE). Method Totally 60 HIE child patients were selected as the subjects and they were divided into three groups:the mild group,the moderate group and the severe group in terms of the severity,20 patients in each group.The 1st,7th,14th and 21st day were the time points after the seizure,the ELISA method was employed to detect the levels of MMP-9.Electroencephalography (aEEG) was also monitored with an observing table to record the clinical data. Results The detected levels of MMP-9 were different in different time points for the HIE with the same severity.The different levels of MMP-9 in different time points in the HIE mild group showed no statistic significance (P>0.05).The HIE moderate group and the HIE severe group showed statistic significances (P<0.05).The detected levels of MMP-9 were also different at the same time point for the HIE with the different severity.The 1st day MMP-9 levels showed statistic significance (P＜0.05) among the three groups.The 7th day showed statistic significance between the mild and moderate group,between the moderate and severe group (P＜0.05).The 14th and 21st day showed statistic significance between the mild and severe group (P＜0.05).The 21st day showed statistic significance between the MMP-9 with different prognoses (P＜0.05),and there was a weak correlation between MMP-9 levels and the HIE prognosis (P=0.007).On the 1st,14th and 21st day,the MMP-9 levels changed in certain correlation with the 60 cases (P<0.05). Conclusions The levels of the cerebrospinal fluids MMP-9 are in correlation with the severity of HIE and can be used as an indicator for the early treatment and prognosis of HIE.
Key words
full-term newborns /
hypoxic-ischemic encephalopathy /
matrix metalloproteinase-9
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Kurinczuk JJ,White-Koning M,Badawi N.Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy[J].Early Hum Dev,2010,86(6):329-338.
[2] Gadzinowski J,Gulczyńska E,Michniewicz B,et al.The use of therapeutic whole body cooling in treating hypoxic-ischemic encephalopathy in the newborn the first case in Poland[J].Ginekol Pol,2012,83(8):630-632.
[3] 邵肖梅,叶鸿瑁,丘小汕.实用新生儿学[J].4版.北京:人民卫生出版社,2011:700-706.
[4] Drury PP,Bennet L,Gunn AJ.Mechanisms of hypothermic neuroprotection[J].Semin Fetal Neonatal Med,2010,15:287-292.
[5] Petzold A.Glialfibrillary acidic protein is a body fluid biomarker for glial pathology in human disease[J].Brain Res,2015,1600:17-31.
[6] Bauer AT,Bürgers HF,RabieT,et al.Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement[J].J Cereb Blood Flow Metab,2010,30(4):837-48.
[7] Teunissen CE,TumaniH,BennettJL,et al.Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies[J].Mult Scler Int,2011,18(6):e1-9.
[8] ShalakL,PerlmanJM.Hypoxic-ischemic brain injury in the term infant-current concepts[J].Early Hum Dev,2004,80(20):125-141.
[9] 王钰,尹晓娟.新生儿缺氧缺血性脑损伤潜在的靶向治疗[J].中华临床医师杂志,2013,28(5),352-355.
[10] DupontTL,ChalakLF,Morriss MC,et al.Short-term outcomes of newborns with perinatal acidemia who are not eligible for systemic hypothermia therapy[J].J Pediatr,2013,162(1):35-41.
[11] Savage WJ,EverettAD.Biomarkers in pediatrics:children as biomarker orphans[J].Proteomics Clin Appl,2010,4(12):915-921.
[12] Nissi R,Talvensaari-Mattila A,Kotila V,et al.Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancyfailure[J].Reprod Biol Endocrinol,2013,11(2):e1-6.
[13] Brackmann FA,Link AS,Jung S,et al.Activin A regulation under global hypoxia in developing mouse brain[J].Brain Res,2013,1531(19):65-74.
PDF(579 KB)
